CClinicalTrials.gg
RecruitingNCT06175754Updated Feb 5, 2025

Laser Treatment of Reticular Leg Veins Vs. Sclerotherapy

An interventional study of Laser ablation and Laser with Sclerotherapy in Reticular Leg Veins, sponsored by Derzhavin Tambov State University. Recruiting at 1 site in Russian Federation. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-05.

Sponsored by Derzhavin Tambov State University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

Treatment of reticular veins with a 1064 nm long-pulsed Nd:YAG laser and combination of a 1064 nm Nd:YAG long pulse laser and sclerotherapy should be no less effective than sclerotherapy alone, and have a frequency of adverse events less then sclerotherapy alone.

Read the detailed description

Reticular leg veins are mostly an aesthetic problem. Sclerotherapy is considered the gold standard for treatment them. However, this method has a high frequency of long persistent hyperpigmentation which decreases the patients' satisfaction. It is a reason to find another method of treatment. Another possible technique to treat reticular veins is the Nd:YAG long pulse 1064 nm transdermal laser or Nd:YAG laser combined with injection sclerotherapy. There are a few studies comparing sclerotherapy with laser treatment and combined treatment with sclerotherapy. But there are no prospective, randomized, comparative clinical trials of all three methods: the 1064 nm Nd:YAG long pulse laser, combined treatment of a 1064 nm Nd:YAG long pulse laser with sclerotherapy and sclerotherapy alone. The aim of current study is the efficacy assessment of the 1064 nm long-pulsed Nd:YAG laser, combined treatment of the 1064 nm Nd:YAG long pulse laser with sclerotherapy and sclerotherapy alone for the treatment of reticular leg veins and analysis of side effects to establish advantages and disadvantage of these methods and find the best option for treatment of reticular leg veins.

02

Conditions studied

  • Reticular Leg Veins

Keywords

  • reticular veins
  • long-pulsed Nd:YAG laser
  • sclerotherapy
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • women over 18
  • reticular veins
  • signed informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • diabetes mellitus
  • pregnancy or lactation
  • malignant neoplasms
  • inability or unwillingness of the patient to wear compression stockings
  • hypersensitivity to the polidocanol, cold, sunlight
  • concomitant diseases: bronchial asthma, severe liver and kidney disease, acute thrombosis and thrombophlebitis, infection of the skin and/or soft tissues, infectious diseases, arteriosclerosis, diabetic angiopathy, heart defects requiring surgery, fever, toxic hyperthyroidism, obesity, tuberculosis, sepsis, violation of the cellular composition of the blood, all diseases requiring bed rest, heart disease with decompensation phenomena,
  • known hereditary thrombophilia.
  • period after treatment of alcoholism
  • reception of oral contraceptives
  • sedentary lifestyle
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
174 participants (estimated)

Study arms

  • Active comparator
    Laser

    to take photo of problem area in the patient's standing position in the room with artificial lighting using the Canon SX510 HS from a distance of 50 cm. to measure the maximum diameter of telangiectasia using the Ultrasound Mindray M7 . to treat the reticular vein by the Nd:YAG laser with a wavelength of 1064 nm, a 7 mm spot, pulse length of 50 msec and fluency 140 J/cm2

    Procedure: Laser ablation

  • Active comparator
    Laser with Sclerotherapy

    to take photo of problem area in the patient's standing position in the room with artificial lighting using the Canon SX510 HS from a distance of 50 cm. to measure the maximum diameter of telangiectasia using the Ultrasound Mindray M7 . to treat the reticular vein by the Nd:YAG laser with a wavelength of 1064 nm, a 7 mm spot, pulse length of 15 msec and fluency 70 J/cm2 to inject the 0.3% foam polidocanol with a 5 ml luer-lock syringe through 30 G needle into reticular vein until the vessel disappears.

    Procedure: Laser with Sclerotherapy

  • Active comparator
    Sclerotherapy

    to take photo of problem area in the patient's standing position in the room with artificial lighting using the Canon SX510 HS from a distance of 50 cm. to measure the maximum diameter of telangiectasia using the Ultrasound Mindray M7 . to inject the 0.5% foam polidocanol with a 5 ml luer-lock syringe through 30 G needle into reticular vein until the vessel disappears.

    Procedure: Sclerotherapy

Interventions

  • ProcedureLaser ablation

    Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser

  • ProcedureLaser with Sclerotherapy

    Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser plus sclerotherapy

  • ProcedureSclerotherapy

    Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy

05

What researchers measure

Primary outcomes

  1. Disappearance of the reticular vein

    The clearing of the vessels on the six-point scale (from 0 to 5 points): 5 - total disappearance of the matting (100% efficacy), 4 - disappearance of around 80%, 3 - disappearance of around 60%, 2 - disappearance of around 40%, 1 - disappearance of around 20%, 0 - no changes.

    Time frame: 6 months

Secondary outcomes

  1. Pain during the procedure: Numerical Rating Scale

    Estimate of the pain on Numerical Rating Scale. Numerical Rating Scale \[NRS\] is a measure of pain intensity from 0 to 10 points.

    Time frame: immediately after the procedure

  2. Patient Satisfaction After Treatment

    Assessment of patient satisfaction on the 3-point scale : no result (0 points), incomplete satisfaction (1 point), complete satisfaction (2 points)

    Time frame: 6 months

  3. Intensity of hyperpigmentation

    Assessment of Intensity of hyperpigmentation on Skin Hyperpigmentation Index (SHI)

    Time frame: 6 months

06

Study locations

1 of 1 sites recruiting
  • Bukina Oksana Vasilyevna
    Tambov, 392002, Russian Federation
    Recruiting
07

References and documents

Publications

  • Nyamekye IK. European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. J Med Vasc. 2022 Apr;47(2):53-55. doi: 10.1016/j.jdmv.2022.04.003. Epub 2022 May 23. No abstract available. PubMed 35691663 ↗
  • Georgiev M. Postsclerotherapy hyperpigmentations: a one-year follow-up. J Dermatol Surg Oncol. 1990 Jul;16(7):608-10. doi: 10.1111/j.1524-4725.1990.tb00088.x. PubMed 2362024 ↗
  • Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy. Etiology, prevention, and treatment. Dermatol Surg. 1995 Jan;21(1):19-29; quiz 31-2. doi: 10.1111/j.1524-4725.1995.tb00107.x. PubMed 7600016 ↗
  • Parlar B, Blazek C, Cazzaniga S, Naldi L, Kloetgen HW, Borradori L, Buettiker U. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):549-54. doi: 10.1111/jdv.12627. Epub 2014 Jul 28. PubMed 25069999 ↗
  • Ianosi G, Ianosi S, Calbureanu-Popescu MX, Tutunaru C, Calina D, Neagoe D. Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Exp Ther Med. 2019 Feb;17(2):1106-1112. doi: 10.3892/etm.2018.6985. Epub 2018 Nov 16. PubMed 30679981 ↗
  • Ozden MG, Bahcivan M, Aydin F, Senturk N, Bek Y, Canturk T, Turanli AY. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. J Dermatolog Treat. 2011 Jun;22(3):162-6. doi: 10.3109/09546631003649679. Epub 2010 Jul 28. PubMed 20666669 ↗
  • Rogachefsky AS, Silapunt S, Goldberg DJ. Nd:YAG laser (1064 nm) irradiation for lower extremity telangiectases and small reticular veins: efficacy as measured by vessel color and size. Dermatol Surg. 2002 Mar;28(3):220-3. doi: 10.1046/j.1524-4725.2002.01141.x. PubMed 11896772 ↗
  • Sadick NS. Laser treatment with a 1064-nm laser for lower extremity class I-III veins employing variable spots and pulse width parameters. Dermatol Surg. 2003 Sep;29(9):916-9. doi: 10.1046/j.1524-4725.2003.29250.x. PubMed 12930332 ↗
  • Moreno-Moraga J, Smarandache A, Pascu ML, Royo J, Trelles MA. 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology. 2014 Dec;29(10):658-66. doi: 10.1177/0268355513502786. Epub 2013 Aug 29. PubMed 23989971 ↗
  • Fonseca MM, Mocelin FJ, Grill MH, Gianesini S, Miyake K, Argenta R, Pereira AH. Nd:Yag laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias (CLaCS method): A triple-blind randomized clinical trial comparing two sclerosing agents associated with same laser patterns. Phlebology. 2023 Apr;38(3):165-171. doi: 10.1177/02683555231153533. Epub 2023 Jan 19. PubMed 36657386 ↗

Individual participant data

Plan to share: Yes — The study data are available to all investigators in the chronic vein disease registry

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

08

Registry details

Key details

Study ID
NCT06175754
Lead sponsor
Derzhavin Tambov State University
Responsible party
Oksana Bukina (Director, Clinical Research, Derzhavin Tambov State University) — Principal investigator
First posted
Dec 19, 2023
Start date
Oct 9, 2023
Primary completion
Jul 9, 2025 (estimated)
Completion
Dec 9, 2025 (estimated)
Last update
Feb 5, 2025

Study contacts

Oksana V Bukina, PhD
Contact
ovsafonova@yandex.ru
+79051204983
Gusen I Kurbanov
Contact
alpha297@mail.ru
+79622348861
Oksana V Bukina, PhD
principal investigator · Derzhavin Tambov State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion